Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02120898 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Participants With Actinic Keratoses
A Phase 3 study, sponsored by Actavis.
- Completed
- Registry status
- Phase 3
- Development phase
- 467
- Enrollment target
NCT02120898 is a Phase 3 study that has completed, run by Actavis. The registered enrollment target is 467 participants.
The verdict
NCT02120898, a Phase 3 study, has completed, sponsored by Actavis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 467 participants
- Enrollment target
Study Summary
The purpose of this study it so compare the safety and efficacy profiles of a generic imiquimod 2.5% cream to the reference listed Zyclara® (imiquimod) cream in the treatment of actinic keratosis (AK).
Interventions
- DRUG Imiquimod
- DRUG Vehicle Cream
- DRUG Zyclara®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 467 participants |
| Start Date | 2013-10-10 |
| Est. Completion | 2014-04-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02120898
The ClinicalTrials.gov registry entry for NCT02120898 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 467 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actavis, which has 79 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Imiquimod is the first listed.
NCT02120898 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02120898 about?
NCT02120898 is a clinical study titled "A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Participants With Actinic Keratoses". The purpose of this study it so compare the safety and efficacy profiles of a generic imiquimod 2.5% cream to the reference listed Zyclara® (imiquimod) cream in the treatment of actinic keratosis (AK).
What is the current status of trial NCT02120898?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 467 participants. The study started on 2013-10-10. Estimated completion is 2014-04-30.
What interventions are being tested in trial NCT02120898?
The interventions under investigation include: Imiquimod (DRUG), Vehicle Cream (DRUG), Zyclara® (DRUG).
Who is sponsoring clinical trial NCT02120898?
This trial is sponsored by Actavis, which has 79 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.